Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

About VYVANSE

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if your child develops symptoms that suggest heart problems, such as chest pain or fainting.

VYVANSE should not be taken if your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
(Date:8/22/2014)... August 22, 2014 Testosterone treatment ... in U.S. courts on behalf of men who ... use of prescription low testosterone therapies, Bernstein Liebhard ... claim was filed against Pfizer Inc. on July ... life-threatening heart issues due to his use of ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Dayton, Ohio (PRWEB) August 22, 2014 Dayton ... patient care tower as part of a $141 million campus ... new patient care tower were unveiled to the public. ... campus facilities plan that will create a campus that meets ... the future. These new care spaces will embody Dayton Children’s ...
(Date:8/22/2014)... 2014 Menstrual leaks risk stains and ... Fla., decided that there needed to be a better ... and producible in design variations, the Safety Net optimizes ... which avoids embarrassment and promotes peace of mind. The ... , The original design was submitted to the Fort ...
(Date:8/22/2014)... News) -- Many children get anxious or afraid when ... a number of ways that parents can make these ... The first step is to explain to children in ... health, said Rita John, director of the pediatric primary ... Nursing in New York City. "Children need to ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2
... could ease sickle-cell disease and thalassemia , ... ... Hospital Boston ( www.childrenshospital.org ) and Dana-Farber Cancer Institute have ... a form of hemoglobin normally made only before birth or ...
... Toy Safety Program Offers Manufacturers A Way to Improve Toy ... Improvement Act , , ANN ... generate concerns among consumers about the safety of their children,s ... Safety team offers a solution -- integrated services that include ...
... 4 Omron Healthcare, Inc. reminds,consumers to take full ... (FSA,s) before they expire by purchasing products to take,control ... blood pressure,monitors and nebulizers. , ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081204/AQTH541-b ...
... Nash Corporation (Nasdaq: KNSY ) is scheduled to participate ... 2008 RBC Capital Markets Healthcare Conference. , , ... the panel discussion on Thursday, December 11th at 11:00 a.m. ET ... The conference is by invitation only, however individuals can listen ...
... of vigorous activity a week , , THURSDAY, Dec. 4 ... in the United States last year met the 2008 ... those people met the Healthy People 2010 physical activity ... , According to the 2008 guidelines, released in October ...
... family today unveiled,the details of a successful holiday party held ... possible by Biel,s Make The Difference,Network, included numerous recording artists ... spirit to children at the hospital. , ... well as seeing some of the,great artists we had at ...
Cached Medicine News:Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:NSF International Offers Answers to Rising Toy Safety Concerns 2Health News:Maximize Flex Spending Account Funds Before They Expire 2Health News:Maximize Flex Spending Account Funds Before They Expire 3Health News:Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3Health News:Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles 2
The Heine C series binocular loupes offer extremely low weight (46 g), crisp views, and quality German construction in an affordable instrument....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Easyloupes are exceptional optics that you have come to expect from Oculus. Available in either 1.8x or 2.5x magnification and 40 cm working distance (15.75 inches), they have the well-known durabili...
... implant is a device that delivers ... Cytomegalovirus (CMV) Retinitis. This approach can ... compared with conventional intravenous treatment. The ... a polymer-based system that slowly releases ...
Medicine Products: